China NMPA approves Zai Lab’s TIVDAK for recurrent or metastatic Cervical cancer

CDSCO approves Trastuzumab deruxtecan plus Pertuzumab for first-line HER2-positive metastatic Breast cancer

U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer

Daiichi Sankyo Korea and AstraZeneca Korea received approval for two additional Enhertu indications: 1L HER2-positive...

Blenrep approved in China for treatment of 2L+ relapsed/refractory multiple myeloma

Disitamab Vedotin approved in china as first line therapy for HER2 expressing urothelial carcinoma

ENHERTU followed by THP approved in China as the first and only HER2 directed ADC...

Chugai obtains regulatory approval for Lunsumio and Polivy combination therapy for additional indication of relapsed...

Kelun-Biotech announces fourth indication for Sacituzumab Tirumotecan (sac-TMT) approved by NMPA in HR+/HER2- breast cancer